{"id":19900,"date":"2023-02-10T08:54:02","date_gmt":"2023-02-10T08:54:02","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/se\/?page_id=19900"},"modified":"2026-02-04T12:08:48","modified_gmt":"2026-02-04T12:08:48","slug":"charles-morris","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/","title":{"rendered":"CHARLES MORRIS"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Portrait\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

https:\/\/www.linkedin.com\/in\/charles-morris-35b52035\/<\/a><\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
Neuraxpharm<\/a><\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

CHARLES MORRIS<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Charles Morris is Chief Corporate Development Officer and joined Neuraxpharm in January 2022. Charles is a seasoned M&A professional with 20 years of experience in investment banking and corporate M&A in the pharmaceutical industry, across multiple geographies, including the US, Germany and Spain.<\/p>

Before joining Neuraxpharm, Charles was Global Head of M&A and Corporate Development at Almirall (2019-2021) and prior to this he was Vice President, Head of M&A, Pharma General Medicine & Animal Health at Bayer AG (2010-2019). Earlier in his career, Charles worked in investment banking and equity research for Bank of America, Merrill Lynch and Molecular Securities in New York.<\/p>

Charles holds an MBA from Columbia Business School (USA) and an undergraduate degree in Economics and Political Science from Emory University (USA).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

https:\/\/www.linkedin.com\/in\/charles-morris-35b52035\/ Neuraxpharm CHARLES MORRIS Charles Morris is Chief Corporate Development Officer and joined Neuraxpharm in January 2022. Charles is a seasoned M&A professional with 20 years of experience in investment banking and corporate M&A in the pharmaceutical industry, across multiple geographies, including the US, Germany and Spain. Before joining Neuraxpharm, Charles was Global Head of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1998,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"class_list":["post-19900","page","type-page","status-publish","hentry"],"yoast_head":"\nCharles Morris - Neuraxpharm SE<\/title>\n<meta name=\"description\" content=\"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CHARLES MORRIS\" \/>\n<meta property=\"og:description\" content=\"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm SE\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T12:08:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/se\/wp-content\/uploads\/sites\/29\/2023\/03\/charles-morris.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/\",\"name\":\"Charles Morris - Neuraxpharm SE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/wp-content\\\/uploads\\\/sites\\\/29\\\/2023\\\/03\\\/charles-morris.jpg\",\"datePublished\":\"2023-02-10T08:54:02+00:00\",\"dateModified\":\"2026-02-04T12:08:48+00:00\",\"description\":\"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/#primaryimage\",\"url\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/29\\\/2023\\\/03\\\/28070546\\\/charles-morris.jpg\",\"contentUrl\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/29\\\/2023\\\/03\\\/28070546\\\/charles-morris.jpg\",\"width\":716,\"height\":700,\"caption\":\"Portrait\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/charles-morris\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Us\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Executive Committee\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/about-us\\\/executive-committee\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"CHARLES MORRIS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/\",\"name\":\"Neuraxpharm SE\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/se\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Charles Morris - Neuraxpharm SE","description":"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris","og_locale":"sv_SE","og_type":"article","og_title":"CHARLES MORRIS","og_description":"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.","og_url":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/","og_site_name":"Neuraxpharm SE","article_modified_time":"2026-02-04T12:08:48+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/se\/wp-content\/uploads\/sites\/29\/2023\/03\/charles-morris.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/","url":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/","name":"Charles Morris - Neuraxpharm SE","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/se\/wp-content\/uploads\/sites\/29\/2023\/03\/charles-morris.jpg","datePublished":"2023-02-10T08:54:02+00:00","dateModified":"2026-02-04T12:08:48+00:00","description":"L\u00e4r k\u00e4nna Charles Morris, Chief Corporate Development Officer p\u00e5 Neuraxpharm. Uppt\u00e4ck hans expertis inom M&A och l\u00e4kemedelsindustrin.","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/29\/2023\/03\/28070546\/charles-morris.jpg","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/29\/2023\/03\/28070546\/charles-morris.jpg","width":716,"height":700,"caption":"Portrait"},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/charles-morris\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.neuraxpharm.com\/se\/"},{"@type":"ListItem","position":2,"name":"About Us","item":"https:\/\/www.neuraxpharm.com\/se\/about-us\/"},{"@type":"ListItem","position":3,"name":"Executive Committee","item":"https:\/\/www.neuraxpharm.com\/se\/about-us\/executive-committee\/"},{"@type":"ListItem","position":4,"name":"CHARLES MORRIS"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/se\/#website","url":"https:\/\/www.neuraxpharm.com\/se\/","name":"Neuraxpharm SE","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/pages\/19900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/comments?post=19900"}],"version-history":[{"count":5,"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/pages\/19900\/revisions"}],"predecessor-version":[{"id":20313,"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/pages\/19900\/revisions\/20313"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/pages\/1998"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/se\/wp-json\/wp\/v2\/media?parent=19900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}